What Drives Pharma IT Cost — and What a Proposal Should Specify
What actually drives pharmaceutical IT costs, what sits outside a base managed IT scope, and what a serious proposal should specify before you sign.
Pharmaceutical IT costs are driven less by headcount than by regulatory scope and system count — and in this industry, a monthly number quoted without a defined scope tells you almost nothing. Two companies with identical headcount can differ by a factor of five depending on what they actually run. This article explains what drives pharmaceutical IT costs, what changes as a company grows from 20 to 150 employees, what sits outside a base managed IT scope, and what a serious proposal should specify before you sign.
What actually drives pharma IT cost?
See how your IT actually stacks up.
Twelve questions, about four minutes, and your score appears on screen immediately — no sales call required.
Users and devices matter less than people assume. What actually drives cost is how many validated systems you run, whether you have lab instrumentation, whether you manufacture, your audit frequency, how many sites you operate, and whether you hold or are pursuing regulatory approvals. A 30-person company with a GMP facility costs more to support than a 60-person company that outsources manufacturing. The same headcount can sit at very different price points depending on these drivers, which is why any per-user number quoted without a scope definition is nearly meaningless.
What does a 20-person company need?
Typically pre-commercial or early clinical. At this stage the scope is foundational: identity and email (Microsoft 365 or Google Workspace), basic endpoint protection, backups, a documented network, and help desk for the team. Validated systems are usually limited or not yet in scope; lab instrumentation may exist but often isn't integrated; manufacturing is outsourced or not yet started.
What people over-buy at this stage: enterprise-grade security tooling they don't yet have the staff to operate, redundant backup layers, and Microsoft 365 tiers above what the team actually uses. A 20-person company rarely needs E5 across the board. What they under-buy: documentation and account ownership. Many small pharma companies discover at their first audit that their domain, their tenant, or their backups live in a provider's account rather than their own.
What drives the cost up at this stage: the first validated system, the first lab instrument that needs to be integrated, and the moment manufacturing moves in-house. Each one adds controlled-documentation and audit-readiness obligations that the foundational scope doesn't cover.
What does a 50-person company need?
What changes: more validated systems, a real quality function, the first serious audits, and often the first commercial systems. At this stage you may be running a LIMS or an eQMS, supporting lab instrumentation, preparing for or responding to FDA inspections, and operating across more than one site or a manufacturing relationship that demands oversight.
The IT scope broadens accordingly. You need validated-system support — not just keeping a system running, but keeping it running inside a controlled, documented, audit-defensible state. You need backup and recovery that accounts for validated data. You need an incident process that quality can trace. And you need a provider (or internal function) that can speak to an auditor without panicking.
What drives the cost up at this stage: every additional validated system, every additional site, and the audit cadence itself. A company with a single LIMS and one site is a different scope from one running LIMS, eQMS, and lab instrumentation across two facilities — even at the same headcount.
What does a 150-person company need?
At 150 employees the shape of IT changes structurally rather than just growing. Multiple sites, manufacturing or extensive outsourced-manufacturing oversight, SOX-level controls if the company is public, and usually a real internal IT or quality-systems function working alongside the external provider. The provider's role shifts from "run everything" toward "run the foundation and partner with the internal team on the validated and regulated estate."
What drives the cost up at this stage: the number of validated systems, the audit cadence, the site count, and whether you're carrying SOX or equivalent financial-controls overhead on top of GxP. Two 150-person companies can differ by a factor of two or more on monthly cost for the same headcount, entirely on the strength of those drivers. If a provider quotes you a flat per-seat number at this size without scoping any of the above, that's the signal to ask harder questions.
Why we don't publish a price for regulated environments
A monthly number means nothing without defined scope, and in pharma the scope varies more than in any other industry we work in. Two companies with identical headcount can differ by a factor of five depending on what they actually run — how many validated systems, whether they manufacture, how many sites, what their audit cadence is, and which regulatory frameworks they hold or are pursuing.
Publishing a range would mislead in both directions. It would anchor some readers too low — a company with a GMP facility and three validated systems would assume the bottom of any range applies to them, and be wrong. It would frighten others away from a conversation they should be having, because a number divorced from scope reads as a price rather than a starting point.
What we will do instead is tell you exactly what drives the number, which is the rest of this article. By the end of it you can see why a proposal that won't define scope is the thing to be afraid of, not a proposal that takes a scoping call seriously.
What sits outside a base managed IT scope
This is the most important thing to understand about pharmaceutical IT costs. General managed IT — helpdesk, monitoring, patching, endpoint security, licensing, standard backup — is the foundation. Regulated environments layer substantial additional scope on top of that foundation, and each layer is scoped and priced separately:
- Validation and revalidation of GxP systems, including IQ/OQ/PQ documentation
- Audit defense and last-line audit support — engineers present during FDA and customer audits, evidence production, response to findings
- Quality systems governance — change control, periodic review, documentation upkeep
- Data integrity controls and ALCOA+ alignment
- Legal and eDiscovery support — litigation hold, retention enforcement, record production
- SOX IT general controls for public or pre-IPO companies
- Computer system inventory and risk classification maintenance
- Supplier and vendor qualification support
- Site-by-site infrastructure for multi-facility and manufacturing operations
- 24/7 coverage commitments for manufacturing or clinical operations
Each of these is scoped individually. A base managed IT figure does not include them, and any provider implying otherwise has not understood the environment. The corollary is that a per-seat comparison between a general-business provider and a regulated-environment provider is not a comparison at all — the scope behind the two numbers is different.
What's usually excluded from the monthly number?
Even within the foundation, the monthly retainer is never the whole bill. Typically excluded: hardware (servers, laptops, network gear), third-party licenses (Microsoft 365, specialized lab or quality software), validation project work, major migrations, and office builds or infrastructure projects.
How those are handled matters as much as the retainer itself. We pass hardware and third-party licenses through at cost — the invoice we receive is the invoice you receive, with no markup. Other providers mark up these lines, sometimes substantially, and that's where a low retainer can turn into a high total cost of ownership. The difference between two proposals at the same monthly number can live entirely in how the excluded items are priced. We wrote about that structural incentive separately in why your MSP recommends what it recommends.
Provider versus internal hire
This is covered fully in a separate article, so I'll keep it brief. The fully-loaded cost of one IT hire — salary, benefits, taxes, tools — is comparable to or above a managed IT retainer, and that one person cannot cover after-hours, vacation, specialist depth across networking, security, and validation, or audit support. A provider buys you a team for the price of one person. The trade-off is control and proximity; some companies prefer an internal hire for cultural reasons, and that's a legitimate choice. It's rarely the cheaper one at this scale.
What should a proposal contain?
A serious proposal specifies more than a price. It should include, at minimum:
- 1.Response-time definitions — what "critical" actually means in minutes, and what the tiers below it are.
- 2.What "unlimited" excludes — most retainers say unlimited help desk; the exclusions are where the limits hide.
- 3.Validated-system scope — which systems are covered, and what "covered" means during an audit.
- 4.Audit support terms — whether audit attendance and documentation are included or billed separately.
- 5.License ownership — whose tenant the licenses sit in, and what happens to them if you leave.
- 6.Renewal and termination terms — notice periods, auto-renewal triggers, and what you take with you.
- 7.On-site coverage — whether and how on-site work is handled, and at what cost.
A proposal that won't specify these isn't a proposal; it's a price. Read about how we approach pharma IT support and managed IT generally for the scope behind any number.
Where companies waste money
The same patterns recur across the pharma companies we inherit. Duplicate security tools — two endpoint platforms, two backup systems, an email filter and a separate email security gateway — each bought to solve a problem the last one didn't, none consolidated. Licenses for departed staff, still renewing. Over-tiered Microsoft 365 licensing, where everyone sits on E5 and a quarter of the company uses only email and Office. Validated systems nobody uses, kept alive because decommissioning feels harder than paying the maintenance. And per-incident billing that quietly discourages people from asking for help, which is how small problems become outages.
The fix in every case is the same discipline as reading a proposal: someone reading the invoice line by line and asking what each line is for.
| Dimension | ~20 employees | ~50 employees | ~150 employees |
|---|---|---|---|
| Typical stage | Pre-commercial / early clinical | Clinical-stage, first quality function | Commercial, multi-site or manufacturing |
| Users | ~20 | ~50 | ~150 |
| Validated systems | Few or none | First LIMS/eQMS, lab instrumentation | Multiple validated systems, manufacturing oversight |
| Audit frequency | Rare | First serious audits | Regular inspections; SOX if public |
| What's in scope | Identity, email, endpoint protection, backups, help desk | Above + validated-system support, audit prep, multi-site | Above + internal IT partnership, SOX controls, full GxP estate |
| What's usually excluded | Hardware, licenses, projects | Same | Same, plus validation project work |
The number matters less than what it's attached to
The point of this article isn't to hand you a price. It's to give you the structure to tell whether a proposal is reasonable. A cheap proposal with undefined scope costs more than an expensive one with clear terms, because the cheap one decides what's excluded only after you've signed. The real negotiation is over scope, ownership, and what happens when you leave. Get those right and almost any reasonable number works. Get them wrong and no number is cheap enough.
If you want the regulatory frame that explains why pharma IT is structured the way it is, our article on 21 CFR Part 11 for executives is the companion piece. The number is the last thing to negotiate, not the first.
Every engagement is scoped individually. Regulated environments carry obligations that general managed IT does not, and the difference is substantial. Any figure quoted without a defined scope — ours or anyone's — is not a price, it's a guess.
Hero photo: "Black calculator beside black pen on white printer paper" by Mediamodifier on Unsplash.
Frequently asked questions
Don't see your question? Email info@isectra.com and we'll answer it directly.
Santiago Aristizabal is President & COO at iSectra. He runs the commercial side of the business and writes about what IT actually costs, and why most providers won't say.
Related reading
Get the next post in your inbox.
Signal, once or twice a month. No spam — just the posts worth reading.
Let's see what your IT could feel like.
A senior engineer will review your environment and respond within 24 hours. No sales script, no obligation.
